Objective To discuss the efficacy and safety ofOxaliplatin and Fluorouracilplus irinotecan in second-line treatment of elderly patients with advanced liver cancer. Methods: 60 advanced liver cancer patients, who failed, who failed to treat in the first-line treatment using fluorouracil combined with oxaliplatin , were randomly divided into experimental group(n=60) and control group(n=60). The control group was given intravenous infusion (15min) of 3mg/m2 on 2 d, and also given intravenous infusion (120min) of irinotecan 300mg/m2. On 1 d the experimental group was given intravenous infusion (15min) ofOxaliplatin 7.5mg/kg plus saline 100mL on the basis of the control group. The two groups was two cycles with twenty-one days per cycle.The clinical efficacy, progression free survival , overall survival, and the side effects of the drugs were compared between the experimental group and the control group in elderly patients with advanced liver cancer. Results: The disease progressions were 30% and 56.67% in the experimental group and the control group respectively (P<0.05); the objective response rates were 40% and 16.67% in the experimental group and the control group respectively (P<0.05); the disease control rate was 70% and 43.33% in the experimental group and the control group respectively (P<0.05); the median OS was 14 months (95% CI: 8.7~17.9) in the experimental group and the median OS was 11 months (95% CI: 5.1~13.9) in the control group, more importantly,the difference was significant (P<0.05);the median PFS was 5 months (95%CI: 4.3~7.2) in the control group and the median PFS was 8 months (95% CI: 6.5~8.2) in the experimental group, more importantly,the difference was significant (P<0.05); the myelosuppression, nausea, vomiting, fatigue and transaminase abnormalities were more obvious in the experimental group and the control group, especiallyⅠ-Ⅱ grade toxicity; the incidence of neutropenia in the experimental group was higher than that in the control group (46.67% vs 20.00%, P=0.028); the incidence of nausea and vomiting grade Ⅰ-Ⅱ in the experimental group was higher than that in the control group (43.33% vs 16.67%, P=0.024). Conclusion: Oxaliplatin combined with Fluorouraciland irinotecan in patients with advanced liver cancer could not only improve ORR and DCR, but also prolonged PFS and OS, Although this chemotherapy produced a certain adverse drug reaction, it was acceptable.

Guo-Xiang Zhang, Juan-Ying Chen, Yuan-Ming Ding, Jian-Sheng Wang, Qing Gong and Yi Zhang. Clinical Study of Oxaliplatin Injection and Fluorouracilinjection Plus Irinotecan Injection in the Treatment of Elderly Patients with advanced Liver Cancer. International Journal of Frontiers in Medicine (2021), Vol. 3, Issue 4: 16-22. https://doi.org/10.25236/IJFM.2021.030403.

[1] Wu Fei, Lin Guozhen, Zhang Jinxin. Current situation and trend of malignant tumors in China [J]. China cancer, 2012, 21 (02): 81-85

[2] Chen Wanqing, Zhang Siwei, Zeng Hongmei, et al. Incidence and death of malignant tumors in China in 2010 [J]. China cancer, 2014, 23 (01): 1-10

[3] Li daojuan, Li Qian, he Yutong. Epidemiological trend of liver cancer [J]. Research on cancer prevention and treatment, 2015, 42 (03): 305-310

[4] Meng Yan, Yang Jianwei. Maintenance treatment of metastatic liver cancer [J]. International Journal of pathological science and clinical, 2013, 33 (05): 412-415

[5] Liu Junbao, Zhang Yurong, Qu Tao, et al. Chemotherapy options for metastatic liver cancer after treatment failure of oxaliplatin and irinotecan [J]. Chinese Journal of oncology, 2013, 40 (23): 1464-1467

[6] Ochiai T, Umeki M, Miyake H, et al. Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable liver cancer[J]. Oncol Rep, 2014, 32(3):887-892.

[7] O'Neil B H, Cainap C, Van Cutsem E, et al. Randomized phase II open-label study of mFOLFOX6 in combination with linifanib orOxaliplatin for metastatic liver cancer [J]. Clin liver Cancer, 2014, 13(3):156-163.

[8] Liu Huiyan, Zhang Bin. Clinical study of oxaliplatin or irinotecan combined with capecitabine in the treatment of advanced liver cancer [J]. Chinese Journal of clinical pharmacology, 2013, 29 (04): 243-245

[9] Liu Y, Wu W, Hong W, et al. Raltitrexed-based chemotherapy for advanced liver cancer [J]. Clin Res Hepatol Gastroenterol, 2014, 38(2):219-225.

[10] Wang Z, Ferrer S, Moliner V, et al. QM/MM calculations suggest a novel intermediate following the proton abstraction  catalyzed by thymidylate synthase[J]. Biochemistry, 2013, 52(13):2348-2358.

[11] Wu Ligang, Zhang Wei, Wang Linlin. Clinical study of recombinant human endostatin injection combined with letitrexed injection and oxaliplatin injection in the treatment of advanced liver cancer [J]. Chinese Journal of clinical pharmacology, 2016, 32 (22): 2049-2051

[12] Liu Huiyan, Zhang Bin. Clinical study of oxaliplatin or irinotecan combined with capecitabine in the treatment of advanced liver cancer [J]. Chinese Journal of clinical pharmacology, 2013, 29 (04): 243-245

[13] Liu Jun, Wen Fugang, Li Bin. Observation on the efficacy of letitrexed combined with irinotecan in the treatment of advanced liver cancer [J]. Chinese modern doctor, 2015, 53 (34): 71-73

[14] Zhou Jianhong, Li Guisheng, Li Gaofeng, et al. Study on the efficacy and safety of irinotecan combined with letitrexed in second-line chemotherapy for advanced liver cancer [J]. Chinese general practice, 2013, 16 (5): 555-557

[15] Xie Da Da, Li Ning, Wang Jing Jue, et al. Efficacy of letitrexed combined with irinotecan in the second-line treatment of advanced liver cancer compared with FOLFIRI regimen [J]. Journal of Clinical Oncology, 2013, 18 (02): 140-143

[16] Chen Gang, Wu Dongqiang. Clinical study ofOxaliplatin injection in the adjuvant treatment of local non-small cell lung cancer in the elderly [J]. Chinese Journal of clinical pharmacology, 2016, 32 (21): 1967-1970

[17] Li Baoxiu, Cao Xiaofei, Weng Chengyin, et al.Oxaliplatin and letitrexed combined with irinotecan or oxaliplatin in the treatment of 28 cases of refractory liver cancer [J]. Chinese Journal of practical diagnosis and treatment, 2014, 28 (8): 819-821

[18] Andre T, Bennouna J, Sastre J, et al.Oxaliplatin (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic liver cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).[J]. Journal of Clinical Oncology, 2012, 10(15):13-15.

[19] Liu Jun, Wen Fugang, Li Bin. Observation on the efficacy of letitrexed combined with irinotecan in the treatment of advanced liver cancer [J]. Chinese modern doctor, 2015, 53 (34): 71-73

[20] Yang Jianwei, Lin Jinyuan, Gao Wei, et al. Clinical observation of letitrexed /Oxaliplatin combined with irinotecan or oxaliplatin in the treatment of advanced liver cancer [J]. Journal of Clinical Oncology, 2013, 18 (1): 70-73